Drugs / ZP7570
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04612517 | Oct 2020 → Aug 2021 | — | Zealand Pharma | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT03994549 Comparator | Jun 2019 → Nov 2020 | — | Zealand Pharma | Completed | No outcome recorded |
| Phase 1 | NCT06000891 Comparator | Sep 2023 → Feb 2025 | — | Zealand Pharma | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-06-18 | Zealand Pharma | Results Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide zealandpharma.com ↗
Copenhagen, Denmark, June 18, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces positive topline clinical results from Part 2 of a Phase 1b multiple ascending dose (MAD) trial, investigating safety, tolerability, and clinical effects of 28 weeks of treatment with dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist 1 . |
| 2024-09-09 | Zealand Pharma | Results Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide zealandpharma.com ↗
Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies |
| 2024-05-23 | Zealand Pharma | Results Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide zealandpharma.com ↗
Treatment with dapiglutide at doses of 4 and 6 mg resulted in an observed numerical mean weight loss change from baseline of 2.9% (p=0.483) and 4.3% (p=0.077) after 12 weeks, respectively, compared to 2.2% with placebo (primary endpoint). |
| 2022-06-06 | Zealand Pharma | Results Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity zealandpharma.com ↗
The Phase 1 results of dapiglutide, a GLP-1R/GLP-2R dual agonist, demonstrated dose dependent weight loss of up to 4.3% of baseline body weight after only four weeks of treatment. |
| 2022-05-31 | Zealand Pharma | Results Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide zealandpharma.com ↗
Zealand Pharma has two oral presentations, including Phase 1 clinical data demonstrating significant weight loss with Zealand’s dapiglutide, a novel GLP1/GLP2 dual agonist and preclinical data on the antidiabetic potential of the company’s long-acting amylin analogue ZP8396. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZP7570 | “Eight ascending doses of ZP7570” NCT03994549 ↗ |
| Action | Activate | “Dual GLP-1R/GLP-2R agonist” NCT04612517 ↗ |
| Route | Subcutaneous | “Multiple Subcutaneous Doses of ZP7570” NCT04612517 ↗ |